<table>
<thead>
<tr>
<th>Subject: Hyperbaric Oxygen Therapy (HBOT)</th>
<th>Original Effective Date: 4/08</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number: MCR-050</td>
<td>Revision Date(s): 12/16/09, 1/14/10, 10/31/12, 3/11/15, 6/20/16</td>
</tr>
<tr>
<td>Review Date: 12/16/15</td>
<td>This MCR is no longer scheduled for revisions.</td>
</tr>
</tbody>
</table>

**DISCLAIMER**

This Molina Clinical Review (MCR) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS’s Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Review (MCR) document and provide the directive for all Medicare members. ³

**DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL**

The Undersea and Hyperbaric Medical Society defines systemic hyperbaric oxygen therapy (HBOT) as a treatment in which a patient breathes near 100% oxygen intermittently while inside a treatment chamber at a pressure higher than sea level pressure (i.e., >1 atmosphere absolute; atm abs). Treatment can be carried out in either a mono- or multiplace chamber. The former accommodates a single patient; the entire chamber is pressurized with near 100% oxygen, and the patient breathes the ambient chamber oxygen directly. The latter holds two or more people (patients, observers, and/or support personnel); the chamber is pressurized with compressed air while the patients breathe near 100% oxygen via masks, head hoods, or endotracheal tubes. ⁵²

No standard protocol has been identified for HBOT sessions. Regardless of the type of chamber used, the interval between sessions and the total number of treatments varies according to the severity of the condition and physician treatment plan. HBOT may begin with 1 to 3 treatments per day for up to 1 week and may continue daily for several days to several months. For each treatment, the pressure in the chamber is increased slowly and then held constant for 30 minutes to several hours. ⁴⁰-⁴⁹

Topical oxygen therapy involves the application of gaseous oxygen to a cutaneous wound and can be administered on an outpatient basis in a clinic or medical office setting. To treat an affected hand or foot, a mitten or boot-shaped plastic bag with a gas inlet is attached to the arm or leg with adhesive tape, and the bag is
then pumped full of pure oxygen. Cutaneous lesions that are not located on hands or feet can be treated with a plastic sheet that is sealed around the edges and then filled with oxygen. Regardless of the location of the lesion, oxygen is pumped into the bag or plastic sheet until the pressure reaches 1.004 to 1.04 atmospheres, since the elevated pressure is believed to facilitate diffusion of oxygen into the wound. A pressurized bag sealed around an extremity can exert a tourniquet-like effect; during treatment, some practitioners continuously cycle bag pressure from full pressure to no pressure and back to full every 40 seconds to limit this effect. Treatment protocols vary somewhat but wounds are typically exposed to gaseous oxygen for 16 to 21 hours spread over 4 to 14 treatment sessions per week for 2 to 4 weeks.  

The FDA regulates hyperbaric oxygen (HBO) chambers as Class II medical devices, and there are a number of different chambers (both monoplace and multiplace chambers) that have been cleared for marketing via the 510(k) process (Product Code CBF, hyperbaric chamber). Devices that are not implantable and pose no risk of fatal outcome to the consumer should they malfunction are assigned Class II status and must meet FDA performance standards. Topical oxygen therapy devices are regulated by the FDA as Class II devices, and several devices have been approved via the FDA 510(k) process. 

**RECOMMENDATION**

1. Systemic hyperbaric oxygen therapy is considered medically necessary and may be authorized for any of the following conditions:

   - Acute cyanide poisoning
   - Acute peripheral artery insufficiency
   - Acute traumatic peripheral ischemia or severe crush injuries (Grade III) as an adjunct to conventional treatment when loss of function, limb, or life is threatened
   - Actinomycosis refractory to antibiotics and surgical treatment
   - Air or gas embolism
   - Chronic refractory osteomyelitis as an adjunctive therapy when all of the following criteria are met:
     - documentation of refractory stage 3B or 4B osteomyelitis; and
     - osteomyelitic lesions persist for more than six weeks after treatment is initiated; and
     - no improvement after adequate antibiotic treatments and operative procedure (if a surgical candidate) are performed
   - Gas Gangrene (clostridial myositis and myonecrosis) as an adjunctive therapy to antibiotics and surgical management
   - Necrotizing soft tissue infections (necrotizing fasciitis)
   - Osteoradionecrosis as an adjunct to conventional treatment
Preparation and preservation of compromised skin, preexisting grafts or flaps that are showing signs of failure or necrosis, (not for primary management of wounds)

Soft tissue radionecrosis as an adjunct to conventional treatment

Severe carbon monoxide poisoning

Severe decompression sickness

2. **As an adjunctive treatment in wound care:**

HBOT therapy is considered medically necessary as adjunctive therapy only if there are no measurable signs of healing for minimally 30 days of standard conventional treatment and must be used in addition to standard wound care for all of the following conditions: [ALL]

Severe non-healing Type 1 or 2 Diabetes Mellitus (DM) lower extremity wound due to DM when the following criteria are met:

- Severe wound documented by Wagner grading with 1 or more of the following:
  - Wagner grade 3 wound, deep ulcer to tendon, capsule or bone
  - Wagner grade 4, deep ulcer with abscess, osteomyelitis, or joint sepsis
  - Wagner grade 5, localized gangrene of forefoot or heel; and

- Minimal to no healing following 30 consecutive days of appropriate wound care utilizing moist retentive wound care including ALL of the following:
  - Antibiotic treatment when indicated
  - Evaluation and correction of underlying peripheral vascular disease or neuropathic disease (if applicable)
  - Optimal glycemic control;
  - Optimal nutritional status;
  - Pressure reduction or off-loading
  - Topical wound treatment (e.g., saline, hydrogels, hydrocolloids, alginates)
  - Wound debridement by any means to remove devitalized tissue

---

### CONTINUATION OF THERAPY

Wounds must be evaluated at least every 30 days during administration of HBOT. After initial authorization of up to 30 days of treatment and or 30 treatments total a progress report must be requested prior to authorization of additional HBO treatment.

Continued treatment with HBO therapy is not considered medically necessary if measurable signs of healing have not been demonstrated within any 30 day period of treatment.

### COVERAGE EXCLUSIONS

1. *Topical hyperbaric oxygen therapy* is considered experimental, investigational, and unproven because the clinical efficacy has not been proven for any condition.
2. **Systemic hyperbaric oxygen therapy** is considered not medically necessary and excluded because there is insufficient evidence in the peer reviewed medical literature for any of the following conditions that include but are not limited to:
   - Acute cerebral edema
   - Acute or chronic cerebral vascular insufficiency.
   - Acute thermal and chemical pulmonary damage, i.e., smoke inhalation with pulmonary insufficiency.
   - Aerobic septicemia
   - Anaerobic septicemia and infection other than clostridial
   - Arthritic Diseases
   - AIDS/HIV
   - Alzheimer’s Disease
   - Asthma
   - Bell’s Palsy
   - Cardiogenic shock
   - Cerebral Palsy
   - Chronic peripheral vascular insufficiency
   - Cutaneous, decubitus, and stasis ulcers
   - Depression
   - Exceptional blood loss anemia
   - Hepatic necrosis
   - Migraines
   - Multiple Sclerosis
   - Myocardial infarction
   - Organ storage.
   - Organ transplantation
   - Parkinson’s
   - Pulmonary emphysema
   - Senility
   - Sickle cell anemia.
   - Skin burns (thermal)
   - Spinal cord injury
   - Sports injury
   - Stroke
   - Systemic aerobic infection
   - Tetanus

3. **Absolute Contraindications include ALL of the following conditions:**
   - Pneumothorax
   - Concurrent administration of disulfiram or the antineoplastic agents, bleomycin, cisplatin, doxorubicin, or sulfamylon

<table>
<thead>
<tr>
<th>SUMMARY OF MEDICAL EVIDENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is a large body of published peer-reviewed scientific literature, including systematic reviews and randomized controlled trials that support the effectiveness, safety and improvement of net health outcomes of</td>
</tr>
</tbody>
</table>
HBOT for many conditions including: decompression illness, arterial or air gas embolism, cyanide and carbon monoxide poisoning, gas gangrene, necrotizing infections, soft tissue radionecrosis and osteoradionecrosis, non-healing wounds in diabetes mellitus, peripheral artery insufficiency, actinomycosis, skin grafts and flaps, acute traumatic ischemia or crush injuries and osteomyelitis.

There is insufficient evidence in the published peer-reviewed scientific literature to support HBOT for any of the conditions outlined in the coverage exclusions section above. The published literature is from low quality studies and primarily consists of case series and retrospective reviews with small heterogeneous patient populations, short-term follow-ups and has reported conflicting and various outcome data.

There is insufficient evidence in the peer reviewed medical literature for any condition treated with topical oxygen therapy.

**CODING INFORMATION** THE CODES LISTED IN THIS POLICY ARE FOR REFERENCE PURPOSES ONLY. LISTING OF A SERVICE OR DEVICE CODE IN THIS POLICY DOES NOT IMPLY THAT THE SERVICE DESCRIBED BY THIS CODE IS A COVERED OR NON-COVERED. COVERAGE IS DETERMINED BY THE BENEFIT DOCUMENT. THIS LIST OF CODES MAY NOT BE ALL INCLUSIVE.

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99183</td>
<td>Physician attendance and supervision of hyperbaric oxygen therapy, per session</td>
</tr>
<tr>
<td>G0277</td>
<td>Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval</td>
</tr>
</tbody>
</table>

**ICD-9** Description: [For dates of service prior to 10/01/2015]

<table>
<thead>
<tr>
<th>ICD-9</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>039.0-039.9</td>
<td>Actinomycotic infections</td>
</tr>
<tr>
<td>040.0</td>
<td>Gas gangrene</td>
</tr>
<tr>
<td>250.8</td>
<td>Diabetes with other specified manifestations</td>
</tr>
<tr>
<td>349.9</td>
<td>Neuropathic disease</td>
</tr>
<tr>
<td>443.9</td>
<td>Peripheral vascular disease</td>
</tr>
<tr>
<td>459.9</td>
<td>Ischemia-acute traumatic</td>
</tr>
<tr>
<td>707.1-707.19</td>
<td>Ulcer of lower limbs except pressure ulcers</td>
</tr>
<tr>
<td>729.99</td>
<td>Disorder of soft tissue -soft tissue necrosis</td>
</tr>
<tr>
<td>730.0x</td>
<td>Osteomyelitis</td>
</tr>
<tr>
<td>730.1x</td>
<td>Chronic osteomyelitis, bone necrosis</td>
</tr>
<tr>
<td>870.0-897.7</td>
<td>Wound, nonhealing, see by site, complicated</td>
</tr>
<tr>
<td>900.0x-904.9</td>
<td>Traumatic ischemia, Injury to blood vessel</td>
</tr>
<tr>
<td>925-929.9</td>
<td>Crushing injury</td>
</tr>
<tr>
<td>958.0</td>
<td>Air embolism as an early complication of trauma</td>
</tr>
<tr>
<td>986</td>
<td>Carbon monoxide poisoning (needs additional code for loss of consciousness OR metabolic acidosis)</td>
</tr>
<tr>
<td>989.0</td>
<td>Cyanide poisoning</td>
</tr>
<tr>
<td>993.3</td>
<td>Decompression sickness</td>
</tr>
<tr>
<td>996.52</td>
<td>Skin graft failure or rejection; nonhealing graft of other tissue, not elsewhere classified</td>
</tr>
<tr>
<td>999.1</td>
<td>Air embolism as complication of medical care, not elsewhere classified</td>
</tr>
</tbody>
</table>

**ICD-10** Description: [For dates of service on or after 10/01/2015]

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A42.0-A42.9</td>
<td>Actinomycosis</td>
</tr>
<tr>
<td>A48.0</td>
<td>Gas gangrene</td>
</tr>
<tr>
<td>E08-E11.9</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>F73.89-F73.9</td>
<td>Other peripheral vascular disease</td>
</tr>
<tr>
<td>L97-L97.929</td>
<td>Non-pressure chronic ulcer of lower limb</td>
</tr>
<tr>
<td>M86.30-M86.9</td>
<td>Chronic osteomyelitis</td>
</tr>
<tr>
<td>S07-S07.9</td>
<td>Crushing injury of head</td>
</tr>
</tbody>
</table>
RESOURCE REFERENCES

Government Agencies


Cochrane and other Peer Reviewed Publications


Other Resources
Hayes

Professional Society
   http://www.achm.org/faq-items/what-are-the-approved-indications-for-hyperbaric-oxygen-therapy/
53. Undersea and Hyperbaric Medical Society’s (UHMS) Best Practice Guidelines, Hyperbaric Oxygen Committee. April, 2011. Accessed at: 

Policy reviewed externally by a MD board certified in Podiatric Surgery, Fellow American College of Foot and Ankle Surgeons, Diplomat American Board of Podiatric Surgery. 6/17/2016.